Access to data and to skills specific to AI are among the key challenges pharma companies face to unlock the technology’s ...

This article explores how digital maturity in process design and parameter management can drive significant time and cost savings, streamline tech transfers and ultimately accelerate patient access to ...

Middle molecules with a molecular weight of more than 1,000 are difficult to synthesize due to multiple steps and time-consuming nature, demanding the development of a new approach that can overcome ...

Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...

Speaking this week at BIO CEO, the heads of Septerna, Upstream Bio and Actuate Therapeutics shared lessons from going public ...

Triple click chemistry has revolutionized chemical synthesis with its simplicity and efficiency, allowing for the quick and selective assembly of complex molecules. Now, in a recent study, researchers ...

We now have a glimpse behind the curtain of how Medicare arrives at so-called maximum fair prices of prescription drugs it ...

A complementary drug to combat Alzheimer's disease could target a specific part of the nerve cell protein tau.

Insilico Medicine ( “Insilico”) , a clinical stage generative artificial intelligence (AI)-driven biotechnology company today ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

As part of the funding, Latent Labs aims to leverage generative artificial intelligence to computationally create novel ...